Can biktarvy help Late-Stage HIV patients catch up?
NCT ID NCT04296695
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This completed Phase 4 trial tested the drug Biktarvy in 202 adults newly diagnosed with HIV who had low CD4 counts (under 200) and high viral loads, meaning they started treatment late. Participants received either Biktarvy or a standard three-drug combination. The main goal was to see how many had undetectable virus levels by week 12, with follow-ups at weeks 4, 24, and 48. The study also tracked improvements in immune cell counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
China Liaoning Dalian Public Health Clinical Center
Dalian, Liaoning, China
-
Lanzhou Feike Hospital
Lanzhou, Guansu, China
-
The Guangxi Zhuang Autonomous Region Longtan Hospital
Liuzhou, Guangxi, 545005, China
-
The Second Hospital of Nanjing
Najing, Jiangsu, 210003, China
-
Tianjin Second People's Hospital
Tianjin, 300192, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide)
What this could lead to
If successful, this could confirm that Biktarvy is a safe and effective first treatment for people diagnosed late with HIV, helping them achieve viral suppression and immune recovery.
What could go wrong
This is a completed Phase 4 trial with 202 participants, so results are available but may not apply to all populations. As with any HIV treatment, side effects and drug resistance are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.